ViroPharma full value up to $52 per share in right situation, says Deutsche Bank

theflyonthewall.com

Deutsche Bank sees ViroPharma's base case valuation as $38 per share, but says in an M&A scenario the company's full value could be as high as $52 per share if the potential buyer has a Hereditary Angioedema sales force. Deutsche notes that Shire (SHPG), which has been mentioned as a potential bidder for ViroPharma in media reports, sells a drug for acute HAE.

View Comments